市場調查報告書

人類乳突病毒(HPV)疫苗的全球市場:成長,趨勢,及預測

Human Papillomavirus Vaccine Market - Growth, Trends, and Forecast (2020 - 2025)

出版商 Mordor Intelligence LLP 商品編碼 921257
出版日期 內容資訊 英文 113 Pages
商品交期: 2-3個工作天內
價格
人類乳突病毒(HPV)疫苗的全球市場:成長,趨勢,及預測 Human Papillomavirus Vaccine Market - Growth, Trends, and Forecast (2020 - 2025)
出版日期: 2020年01月01日內容資訊: 英文 113 Pages
簡介

人類乳突病毒(HPV)疫苗市場成長的主要原因,有新的人類乳突病毒(HPV)疫苗的認證,及早期篩檢和疫苗接種的政府及民間組織的措施增加。透過UNICEF供給人類乳突病毒(HPV)疫苗,現在雖然不足以對應增加的需求,但是由於這樣的努力,預計推動該市場的成長。 還有北美在預測期間內預計保持最大的市場佔有率,由於出色的醫療保健基礎設施的存在,美國預計成為最大的人類乳突病毒(HPV)疫苗市場。

本報告提供全球人類乳突病毒(HPV)疫苗市場的相關調查,市場機會和趨勢,成長及阻礙因素,各類型、適應症、地區的市場分析,競爭情形,主要企業的簡介等資訊。

目錄

第1章 簡介

  • 調查成果
  • 調查的前提條件
  • 調查範圍

第2章 調查手法

第3章 摘要整理

第4章 市場動態

  • 市場概要
  • 市場成長要素
    • 新的人類乳突病毒(HPV)疫苗的認證
    • 為了早期篩檢和疫苗接種,政府及民間組織的舉措增加
  • 阻礙市場要素
    • 嚴格法規
  • 波特的五力分析

第5章 市場區隔

  • 各類型
    • 2價值
    • 4價值
    • 9價值
  • 各適應症
    • 子宮頸癌症
    • 肛門癌症
    • 陰莖癌症
    • 中咽癌症
    • 生殖器濕疣
    • 其他
  • 各地區
    • 北美
    • 歐洲
    • 亞太地區
    • 中東、非洲
    • 南美

第6章 競爭情形

  • 企業簡介
    • Merck & Co., Inc.,
    • GlaxoSmithKline plc.
    • Sanofi
    • Johnson & Johnson
    • AstraZeneca
    • Serum Institute of India Pvt. Ltd.
    • Bharat Biotech

第7章 市場機會及今後趨勢

目錄
Product Code: 67089

Market Overview

The major factors for the growth of the human papillomavirus (HPV) vaccine market include the approval of new HPV vaccines, and increasing initiatives by government & private organizations for early screening & vaccination.

The rising government initiatives are expected to propel the overall growth of the market over the forecast period. Also, some of the organizations are focusing on creating a proper supply of products. As per the data published by UNICEF in 2018, the UNICEF human papillomavirus (HPV) vaccine procured over 12.9 million doses in the period 2013-2017. Furthermore, UNICEF procured 84% doses for countries supported by Gavi, the Vaccine Alliance (Gavi), and 16% doses for self-financing middle-income countries (MICs). However, the HPV vaccine supply through UNICEF is currently not sufficient to meet the increased needs, which it projects could reach 50 million doses in 2019. Such types of initiatives are expected to boost the growth of the market.

Scope of the Report

As per the scope of this report, human papillomavirus vaccines are vaccines that are utilized to prevent the HPV infection. HPV is a group of more than 100 viruses, of which 13 can cause cancer and nearly all cases of cervical cancer are attributed to HPV. The market is segmented by type, indication, and geography.

Key Market Trends

Cervical Cancer is the Segment by Indication expected to Hold Largest Market Share over the Forecast Period

Nearly all instances of cervical cancer are caused by human papillomavirus (HPV). Also, there are highly sensitive and specific molecular tests now available to identify from DNA, the high-risk HPV types, in cervical cancer screening. Furthermore, according to the United States National Institute of Health, cervical cancer, was once one of the most common cancers among the US female population, now ranks 14th in frequency. However, rates are still high in developing countries where more than 80% of cervical cancer cases occur. According to the WHO, cervical cancer is the third most common cancer among women and the second most frequent cause of cancer-related death, worldwide, accounting for nearly 300,000 deaths annually. Thus, owing to the rising cases of cervical cancer the market is expected to witness high growth over the forecast period.

North America is Expected to Hold Largest Market Share over the Forecast Period

The United States is expected to be the largest HPV vaccine market owing to the presence of better healthcare infrastructure. As per the data published by the American Sexual Health Association, each year around 14 million new cases of sexually transmitted HPV occur in the United States with at least 79 million people estimated to be currently infected. The rising cases are expected to boost the growth of the market in the United States. Gardasil was the first vaccine approved by the FDA in 2006 to prevent certain cancers and diseases caused by HPV in the United States.

Competitive Landscape

The market studied is a consolidated market owing to the presence of a few major market players. Also, other players have products in the pipeline and these companies are investing heavily in R&D. Some of the major market players are Merck & Co., Inc., GlaxoSmithKline plc., Sanofi, Johnson & Johnson, AstraZeneca, Serum Institute of India Pvt. Ltd., and Bharat Biotech.

Reasons to Purchase this report:

  • The market estimate (ME) sheet in Excel format
  • Report customization as per the client's requirements
  • 3 months of analyst support

Table of Contents

1 INTRODUCTION

  • 1.1 Study Deliverables
  • 1.2 Study Assumptions
  • 1.3 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Approval of New HPV Vaccines
    • 4.2.2 Increasing initiatives by Government & Private Organizations for Early Screening & Vaccination
  • 4.3 Market Restraints
    • 4.3.1 Stringent Regulation
  • 4.4 Porter's Five Force Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION

  • 5.1 By Type
    • 5.1.1 Bivalent
    • 5.1.2 Quadrivalent
    • 5.1.3 Nonavalent
  • 5.2 By Indication
    • 5.2.1 Cervical Cancer
    • 5.2.2 Anal Cancer
    • 5.2.3 Penile Cancer
    • 5.2.4 Oropharyngeal Cancer
    • 5.2.5 Genital Warts
    • 5.2.6 Others
  • 5.3 Geography
    • 5.3.1 North America
      • 5.3.1.1 US
      • 5.3.1.2 Canada
      • 5.3.1.3 Mexico
    • 5.3.2 Europe
      • 5.3.2.1 Germany
      • 5.3.2.2 UK
      • 5.3.2.3 France
      • 5.3.2.4 Italy
      • 5.3.2.5 Spain
      • 5.3.2.6 Rest of Europe
    • 5.3.3 Asia Pacific
      • 5.3.3.1 China
      • 5.3.3.2 Japan
      • 5.3.3.3 India
      • 5.3.3.4 Australia
      • 5.3.3.5 South Korea
      • 5.3.3.6 Rest of Asia-Pacific
    • 5.3.4 Middle East and Africa
      • 5.3.4.1 GCC
      • 5.3.4.2 South Africa
      • 5.3.4.3 Rest of Middle East and Africa
    • 5.3.5 South America
      • 5.3.5.1 Brazil
      • 5.3.5.2 Argentina
      • 5.3.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Merck & Co., Inc.,
    • 6.1.2 GlaxoSmithKline plc.
    • 6.1.3 Sanofi
    • 6.1.4 Johnson & Johnson
    • 6.1.5 AstraZeneca
    • 6.1.6 Serum Institute of India Pvt. Ltd.
    • 6.1.7 Bharat Biotech

7 MARKET OPPORTUNITIES AND FUTURE TRENDS